Israel · Delayed Price · Currency is ILS · Price in ILA Enlivex Company Description
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis.
The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial.
Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026.
The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Oren Hershkovitz |
Contact Details
Address: 14 Einstein Street Ness Ziona, 7403618 Israel | |
| Phone | 972 2 620 8072 |
| Website | enlivex.com |
Stock Details
| Ticker Symbol | ENLV |
| Exchange | Tel Aviv Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IL0011319527 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
| Shai Novik M.B.A. | Executive Chairman |
| Prof. Dror Mevorach M.D. | Founder and Scientific Advisor |
| Shachar Shlosberger CPA | Chief Financial Officer |
| Dr. Veronique Amor-Baroukh | Senior Director of Operations |
| Sigal Arad | Director of Human Resources |
| Dr. Einat Galamidi M.D. | Chief Medical Officer |